Medidata, a Dassault Systèmes company, is pleased to announce that it was recognized for its outstanding accomplishments in life sciences by the Citeline Awards:
- Best Patient-Facing Technology Initiative for myMedidata, a single-destination web-based portal for patients to engage pre-trial, in-trial, and post-trial, built for patients, by patients;
- Best Sponsor-Facing Technology Initiative for Medidata’s Digital Oversight Solution, which facilitates clinical trial data oversight and monitoring, improving timelines, cost, and quality in the execution of decentralized clinical trials (DCTs).
The Citeline Awards celebrate critical achievements across the spectrum of key R&D activities, from successes in early and late-stage research, to advances in technological tools, to innovations in trial design and execution. Medidata was presented with the awards in a ceremony held on April 7 in Boston.
myMedidata was recognized as a powerful, intuitive, patient-centric portal. The Citeline Best Patient-facing Technology Initiative recognizes the growing role of technology in facilitating participation in clinical trials and is awarded to the product which best advances patient data collection and improves overall patient experience. myMedidata enables patients to seamlessly connect with any online device to virtually learn about, enroll in and participate in clinical trial activities. It is the industry’s single most comprehensive, integrated tool set for all aspects of clinical research. It is built on Medidata’s industry leading Rave EDC (Electronic Data Capture) system, currently in use at more clinical research sites globally than any other system.
Medidata’s Digital Oversight Solution was commended for its transformative impact on all core activities of the trial process. Medidata’s Digital Oversight Solution has a unique position in the market, unifying risk management, centralized monitoring, and a robust clinical trial management system (CTMS) on one platform. This solution makes it possible for study teams to prepare for and analyze high volumes of data, at scale and in time to take action. The technology can move teams away from delayed, reactive methodologies to proactive and predictive strategies, as well as optimize physical and virtual interactions with clinical sites.
Sastry Chilukuri, co-CEO of Medidata, said, “The patient’s interest is at the core of what we do, which is why we have worked hard to pioneer products that make clinical trials more accessible and engaging. As the first company to leverage digital health technologies for DCTs, we are proud to have received the Citeline Awards for myMedidata and Medidata’s Digital Oversight Solution. We will continue to support the movement toward trial decentralization with ever-expanding offerings, which deliver high quality data and improve the patient experience.”
Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.